

**CLAIMS**

1. Use of AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, and one of:

- 5      a) 5-FU;  
         b) CPT-11; and  
         c) 5-FU and CPT-11

in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human.

10

2. Use of AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, and one of:

- a) 5-FU;  
         b) CPT-11; and  
15      c) 5-FU and CPT-11

in the manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as a human.

3. Use of AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, and one of:

- 20      a) 5-FU;  
         b) CPT-11; and  
         c) 5-FU and CPT-11

in the manufacture of a medicament for use in the production of an anti-tumour effect in a warm-blooded animal such as a human.

4. Use of AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, and 5-FU in the manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as a human which is being treated with ionising radiation.

5. Use of AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, and CPT-11 in the manufacture of a medicament for use in the production of an

anti-cancer effect in a warm-blooded animal such as a human which is being treated with ionising radiation.

6. Use of AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, and 5-FU and CPT-11 in the manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as a human which is being treated with ionising radiation.
7. Use according to any one of claims 2, 4, 5 and 6 wherein the cancer is colorectal cancer.
8. Use according to any one of claims 1-7 wherein AZD2171 is in a form of the free base.
9. A pharmaceutical composition comprising AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, and 5-FU in association with a pharmaceutically acceptable excipient or carrier.
10. A pharmaceutical composition comprising AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, and CPT-11 in association with a pharmaceutically acceptable excipient or carrier.
11. A pharmaceutical composition comprising AZD2171 or a pharmaceutically acceptable salt thereof, and 5-FU and CPT-11 in association with a pharmaceutically acceptable excipient or carrier.
12. A kit comprising AZD2171 or a pharmaceutically acceptable salt thereof, and 5-FU.
13. A kit comprising AZD2171 or a pharmaceutically acceptable salt thereof, and CPT-11.
14. A kit comprising AZD2171 or a pharmaceutically acceptable salt thereof, and 5-FU and CPT-11.

15. A method for the treatment of a cancer in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171, or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, before, after or simultaneously with an effective amount of one of:

- 5      a) 5-FU;  
         b) CPT-11; and  
         c) 5-FU and CPT-11.

16. A method for the treatment of a cancer in a warm-blooded animal such as a human,  
10 which comprises administering to said animal an effective amount of AZD2171, or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, before, after or simultaneously with an effective amount of one of:

- a) 5-FU;  
         b) CPT-11; and  
15      c) 5-FU and CPT-11;

and before, after or simultaneously with an effective amount of ionising radiation.

17. A method according to claim 15 or claim 16 wherein AZD2171 is in a form of the free base.

20

18. A method for the treatment of a cancer in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 maleate salt, before, after or simultaneously with an effective amount of  
5-FU and CPT-11.

25

19. Use of AZD2171 maleate salt and 5-FU and CPT-11 in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human.

30